| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nucleus Accumbens | 192 | 2021 | 417 | 24.890 |
Why?
|
| Cocaine | 146 | 2023 | 555 | 20.620 |
Why?
|
| Cocaine-Related Disorders | 69 | 2022 | 504 | 13.210 |
Why?
|
| Neuronal Plasticity | 48 | 2023 | 274 | 12.170 |
Why?
|
| Glutamic Acid | 77 | 2020 | 332 | 11.940 |
Why?
|
| Drug-Seeking Behavior | 37 | 2021 | 213 | 10.310 |
Why?
|
| Substance-Related Disorders | 55 | 2021 | 1242 | 8.490 |
Why?
|
| Behavior, Addictive | 38 | 2020 | 317 | 7.750 |
Why?
|
| Rats | 284 | 2022 | 5300 | 7.730 |
Why?
|
| Dopamine | 118 | 2016 | 474 | 7.370 |
Why?
|
| Rats, Sprague-Dawley | 157 | 2021 | 2083 | 7.040 |
Why?
|
| Synaptic Transmission | 57 | 2022 | 236 | 6.440 |
Why?
|
| Synapses | 30 | 2022 | 222 | 6.400 |
Why?
|
| Animals | 374 | 2022 | 20881 | 5.980 |
Why?
|
| Behavior, Animal | 74 | 2020 | 470 | 5.730 |
Why?
|
| Self Administration | 73 | 2022 | 419 | 5.620 |
Why?
|
| Prefrontal Cortex | 51 | 2019 | 640 | 5.430 |
Why?
|
| Acetylcysteine | 29 | 2022 | 296 | 5.320 |
Why?
|
| Motor Activity | 97 | 2022 | 621 | 5.320 |
Why?
|
| Extinction, Psychological | 43 | 2022 | 240 | 5.150 |
Why?
|
| Dopamine Uptake Inhibitors | 28 | 2019 | 152 | 5.050 |
Why?
|
| Neurons | 53 | 2022 | 881 | 5.020 |
Why?
|
| Cues | 37 | 2022 | 654 | 4.870 |
Why?
|
| Receptors, Metabotropic Glutamate | 27 | 2023 | 75 | 4.790 |
Why?
|
| Globus Pallidus | 32 | 2017 | 64 | 4.470 |
Why?
|
| Heroin | 12 | 2022 | 49 | 4.150 |
Why?
|
| Brain | 54 | 2021 | 2176 | 3.870 |
Why?
|
| Neural Pathways | 37 | 2021 | 324 | 3.510 |
Why?
|
| Carrier Proteins | 24 | 2012 | 597 | 3.410 |
Why?
|
| Conditioning, Operant | 26 | 2019 | 241 | 3.250 |
Why?
|
| Substance Withdrawal Syndrome | 23 | 2018 | 435 | 3.170 |
Why?
|
| Heroin Dependence | 8 | 2022 | 23 | 3.070 |
Why?
|
| Dendritic Spines | 17 | 2020 | 76 | 2.990 |
Why?
|
| Male | 269 | 2022 | 37321 | 2.860 |
Why?
|
| Receptors, Dopamine D1 | 15 | 2021 | 87 | 2.830 |
Why?
|
| gamma-Aminobutyric Acid | 23 | 2021 | 208 | 2.710 |
Why?
|
| Tegmentum Mesencephali | 40 | 1999 | 52 | 2.700 |
Why?
|
| Astrocytes | 12 | 2022 | 270 | 2.680 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 20 | 2019 | 266 | 2.480 |
Why?
|
| Recurrence | 35 | 2022 | 948 | 2.400 |
Why?
|
| Receptors, AMPA | 22 | 2019 | 99 | 2.350 |
Why?
|
| Nerve Net | 12 | 2021 | 181 | 2.340 |
Why?
|
| Receptors, Dopamine D2 | 12 | 2021 | 109 | 2.200 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 9 | 2015 | 26 | 2.190 |
Why?
|
| Cerebral Cortex | 16 | 2017 | 415 | 2.170 |
Why?
|
| Nerve Tissue Proteins | 19 | 2019 | 290 | 2.130 |
Why?
|
| Central Nervous System Stimulants | 16 | 2023 | 221 | 2.100 |
Why?
|
| Extracellular Space | 31 | 2009 | 121 | 2.090 |
Why?
|
| Integrin beta3 | 4 | 2020 | 35 | 2.080 |
Why?
|
| Neuropeptides | 9 | 2012 | 106 | 2.070 |
Why?
|
| Ventral Tegmental Area | 18 | 2013 | 74 | 2.000 |
Why?
|
| Microinjections | 46 | 2013 | 130 | 1.880 |
Why?
|
| Exploratory Behavior | 11 | 2022 | 79 | 1.870 |
Why?
|
| Enkephalins | 33 | 2015 | 89 | 1.860 |
Why?
|
| Corpus Striatum | 20 | 2017 | 279 | 1.820 |
Why?
|
| Basal Forebrain | 4 | 2021 | 15 | 1.760 |
Why?
|
| Microdialysis | 32 | 2013 | 147 | 1.730 |
Why?
|
| Adaptation, Physiological | 9 | 2018 | 189 | 1.700 |
Why?
|
| Narcotics | 11 | 2012 | 65 | 1.670 |
Why?
|
| Free Radical Scavengers | 7 | 2019 | 112 | 1.620 |
Why?
|
| Motivation | 8 | 2019 | 561 | 1.600 |
Why?
|
| Reward | 11 | 2022 | 201 | 1.590 |
Why?
|
| Receptors, Glutamate | 10 | 2013 | 22 | 1.590 |
Why?
|
| Neurotensin | 24 | 2008 | 37 | 1.520 |
Why?
|
| Limbic System | 20 | 2009 | 106 | 1.490 |
Why?
|
| Dopaminergic Neurons | 3 | 2020 | 46 | 1.480 |
Why?
|
| Analgesics, Opioid | 8 | 2022 | 498 | 1.470 |
Why?
|
| Cannabidiol | 3 | 2022 | 31 | 1.470 |
Why?
|
| Long-Term Potentiation | 7 | 2013 | 53 | 1.470 |
Why?
|
| Disease Models, Animal | 31 | 2020 | 2550 | 1.460 |
Why?
|
| Dronabinol | 4 | 2022 | 84 | 1.440 |
Why?
|
| Glutamates | 11 | 2022 | 41 | 1.330 |
Why?
|
| Rats, Inbred Strains | 71 | 2001 | 532 | 1.310 |
Why?
|
| Dose-Response Relationship, Drug | 45 | 2017 | 1745 | 1.310 |
Why?
|
| Interneurons | 4 | 2017 | 70 | 1.310 |
Why?
|
| Long-Term Synaptic Depression | 7 | 2019 | 32 | 1.300 |
Why?
|
| Amphetamine | 17 | 2023 | 77 | 1.280 |
Why?
|
| Receptors, Opioid, mu | 15 | 2014 | 70 | 1.280 |
Why?
|
| Alcoholism | 8 | 2022 | 1109 | 1.270 |
Why?
|
| Homeostasis | 8 | 2016 | 291 | 1.250 |
Why?
|
| Models, Neurological | 10 | 2019 | 136 | 1.210 |
Why?
|
| Excitatory Postsynaptic Potentials | 7 | 2018 | 87 | 1.150 |
Why?
|
| Sucrose | 4 | 2021 | 58 | 1.120 |
Why?
|
| Mice | 35 | 2020 | 8474 | 1.100 |
Why?
|
| Analysis of Variance | 18 | 2018 | 1040 | 1.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 18 | 2017 | 128 | 1.080 |
Why?
|
| Humans | 93 | 2022 | 68618 | 1.060 |
Why?
|
| Ethanol | 11 | 2022 | 893 | 1.040 |
Why?
|
| RNA, Messenger | 21 | 2015 | 1664 | 1.020 |
Why?
|
| Methamphetamine | 4 | 2019 | 132 | 0.990 |
Why?
|
| Central Nervous System Depressants | 5 | 2011 | 182 | 0.990 |
Why?
|
| Actins | 8 | 2019 | 249 | 0.970 |
Why?
|
| Homer Scaffolding Proteins | 16 | 2012 | 24 | 0.960 |
Why?
|
| Septal Nuclei | 14 | 2004 | 31 | 0.950 |
Why?
|
| Excitatory Amino Acid Agonists | 12 | 2017 | 59 | 0.930 |
Why?
|
| Actin Depolymerizing Factors | 3 | 2020 | 16 | 0.930 |
Why?
|
| Basal Ganglia | 4 | 2013 | 45 | 0.920 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 12 | 2019 | 21 | 0.920 |
Why?
|
| Neurotransmitter Agents | 9 | 2012 | 102 | 0.920 |
Why?
|
| Excitatory Amino Acid Agents | 2 | 2015 | 20 | 0.910 |
Why?
|
| Receptors, Dopamine | 16 | 2018 | 119 | 0.890 |
Why?
|
| Ceftriaxone | 6 | 2015 | 32 | 0.860 |
Why?
|
| Narcotic Antagonists | 5 | 2020 | 184 | 0.850 |
Why?
|
| Stress, Psychological | 12 | 2020 | 824 | 0.840 |
Why?
|
| Gene Expression Regulation | 11 | 2017 | 1293 | 0.840 |
Why?
|
| Cannabinoids | 2 | 2022 | 90 | 0.840 |
Why?
|
| Dopamine Antagonists | 15 | 2008 | 65 | 0.830 |
Why?
|
| Brain Chemistry | 17 | 2010 | 173 | 0.830 |
Why?
|
| Stilbamidines | 6 | 1999 | 13 | 0.790 |
Why?
|
| Signal Transduction | 8 | 2020 | 2689 | 0.780 |
Why?
|
| Mesencephalon | 14 | 1999 | 41 | 0.780 |
Why?
|
| Frontal Lobe | 7 | 2015 | 156 | 0.780 |
Why?
|
| Cystine | 9 | 2022 | 20 | 0.780 |
Why?
|
| Tobacco Use Disorder | 4 | 2022 | 432 | 0.780 |
Why?
|
| Mice, Transgenic | 9 | 2019 | 1033 | 0.770 |
Why?
|
| Brain-Derived Neurotrophic Factor | 4 | 2018 | 124 | 0.760 |
Why?
|
| Muscimol | 15 | 2010 | 26 | 0.750 |
Why?
|
| Anesthetics, Local | 5 | 2017 | 83 | 0.750 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2019 | 145 | 0.750 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2019 | 160 | 0.740 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2020 | 20 | 0.740 |
Why?
|
| Amygdala | 7 | 2008 | 159 | 0.730 |
Why?
|
| Hypothalamic Area, Lateral | 1 | 2020 | 17 | 0.720 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 57 | 0.710 |
Why?
|
| Baclofen | 11 | 2010 | 24 | 0.710 |
Why?
|
| Substance P | 11 | 1998 | 39 | 0.710 |
Why?
|
| Calcium Channels | 4 | 2014 | 59 | 0.700 |
Why?
|
| GABAergic Neurons | 1 | 2020 | 17 | 0.690 |
Why?
|
| Blotting, Western | 12 | 2013 | 954 | 0.690 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2019 | 68 | 0.690 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2020 | 1506 | 0.690 |
Why?
|
| Oxidative Stress | 7 | 2020 | 718 | 0.680 |
Why?
|
| Time Factors | 26 | 2013 | 4655 | 0.670 |
Why?
|
| Proteomics | 2 | 2011 | 246 | 0.660 |
Why?
|
| Amino Acid Transport System y+ | 5 | 2014 | 13 | 0.650 |
Why?
|
| Locomotion | 10 | 2013 | 135 | 0.650 |
Why?
|
| Secondary Prevention | 10 | 2020 | 291 | 0.640 |
Why?
|
| Receptors, Opioid | 9 | 1992 | 60 | 0.630 |
Why?
|
| Receptors, GABA-A | 9 | 2010 | 89 | 0.620 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 23 | 2001 | 27 | 0.620 |
Why?
|
| Dendrites | 7 | 2011 | 44 | 0.610 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 7 | 2017 | 51 | 0.610 |
Why?
|
| Mental Disorders | 4 | 2022 | 659 | 0.610 |
Why?
|
| Glutamate Plasma Membrane Transport Proteins | 1 | 2017 | 2 | 0.610 |
Why?
|
| Prosencephalon | 4 | 2003 | 38 | 0.580 |
Why?
|
| N-Methylaspartate | 4 | 2019 | 59 | 0.580 |
Why?
|
| Drug Administration Schedule | 14 | 2014 | 567 | 0.570 |
Why?
|
| Methoxyhydroxyphenylglycol | 4 | 2005 | 41 | 0.570 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2017 | 35 | 0.570 |
Why?
|
| Thalamus | 7 | 2004 | 82 | 0.560 |
Why?
|
| GTP-Binding Proteins | 8 | 1993 | 231 | 0.550 |
Why?
|
| Proline | 3 | 2003 | 52 | 0.550 |
Why?
|
| Chromatography, High Pressure Liquid | 9 | 2011 | 381 | 0.550 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 298 | 0.540 |
Why?
|
| Patch-Clamp Techniques | 7 | 2013 | 204 | 0.540 |
Why?
|
| Mice, Inbred C57BL | 14 | 2019 | 2791 | 0.540 |
Why?
|
| Epigenomics | 2 | 2013 | 29 | 0.530 |
Why?
|
| GABA Agonists | 8 | 2013 | 23 | 0.530 |
Why?
|
| Transcription, Genetic | 5 | 2009 | 562 | 0.530 |
Why?
|
| Thinking | 1 | 2016 | 30 | 0.530 |
Why?
|
| Bipolar Disorder | 2 | 2022 | 307 | 0.530 |
Why?
|
| Peptide Fragments | 8 | 2008 | 483 | 0.530 |
Why?
|
| Combat Disorders | 1 | 2016 | 102 | 0.520 |
Why?
|
| Subcellular Fractions | 5 | 2011 | 92 | 0.520 |
Why?
|
| Morpholinos | 2 | 2014 | 8 | 0.520 |
Why?
|
| Amino Acids | 7 | 2012 | 131 | 0.510 |
Why?
|
| Models, Biological | 6 | 2012 | 981 | 0.510 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2015 | 6 | 0.500 |
Why?
|
| Membrane Transport Proteins | 3 | 2004 | 81 | 0.500 |
Why?
|
| Mice, Knockout | 11 | 2017 | 1692 | 0.500 |
Why?
|
| Amino Acid Transport Systems, Acidic | 1 | 2014 | 2 | 0.470 |
Why?
|
| Naltrexone | 5 | 2020 | 195 | 0.470 |
Why?
|
| Amphetamine-Related Disorders | 2 | 2009 | 92 | 0.470 |
Why?
|
| Optogenetics | 4 | 2015 | 20 | 0.470 |
Why?
|
| Phenotype | 4 | 2015 | 947 | 0.470 |
Why?
|
| Choice Behavior | 2 | 2005 | 85 | 0.470 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 236 | 0.460 |
Why?
|
| Extracellular Matrix | 2 | 2015 | 493 | 0.460 |
Why?
|
| Xanthines | 1 | 2013 | 17 | 0.460 |
Why?
|
| Arousal | 6 | 2001 | 168 | 0.450 |
Why?
|
| Microscopy, Confocal | 5 | 2013 | 337 | 0.450 |
Why?
|
| Neostriatum | 4 | 2009 | 60 | 0.450 |
Why?
|
| Cell Count | 7 | 2015 | 248 | 0.450 |
Why?
|
| Extracellular Fluid | 4 | 2008 | 29 | 0.440 |
Why?
|
| Female | 27 | 2022 | 38074 | 0.440 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 167 | 0.440 |
Why?
|
| Models, Psychological | 1 | 2014 | 180 | 0.430 |
Why?
|
| Enkephalin, Methionine | 8 | 1987 | 20 | 0.430 |
Why?
|
| Veterans | 2 | 2020 | 904 | 0.430 |
Why?
|
| Morphine | 7 | 2010 | 76 | 0.430 |
Why?
|
| Central Nervous System Agents | 2 | 2015 | 37 | 0.430 |
Why?
|
| Rats, Long-Evans | 5 | 2020 | 203 | 0.410 |
Why?
|
| Repressor Proteins | 7 | 2012 | 183 | 0.410 |
Why?
|
| Gene Deletion | 4 | 2008 | 235 | 0.410 |
Why?
|
| Diet | 1 | 2015 | 514 | 0.410 |
Why?
|
| Biogenic Monoamines | 3 | 2009 | 18 | 0.410 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2011 | 6 | 0.400 |
Why?
|
| Receptors, GABA | 2 | 2013 | 8 | 0.400 |
Why?
|
| Electroshock | 8 | 2004 | 36 | 0.400 |
Why?
|
| Memory, Short-Term | 2 | 2003 | 79 | 0.400 |
Why?
|
| Environment | 4 | 2013 | 115 | 0.400 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2010 | 216 | 0.390 |
Why?
|
| Inhibitory Postsynaptic Potentials | 2 | 2013 | 25 | 0.390 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2009 | 82 | 0.390 |
Why?
|
| Feeding Behavior | 4 | 2015 | 224 | 0.390 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2011 | 7 | 0.390 |
Why?
|
| Immunohistochemistry | 11 | 2015 | 1174 | 0.390 |
Why?
|
| C-Reactive Protein | 2 | 2010 | 180 | 0.380 |
Why?
|
| Neural Inhibition | 5 | 2015 | 80 | 0.380 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2011 | 306 | 0.370 |
Why?
|
| Neurosciences | 1 | 2010 | 15 | 0.370 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2015 | 92 | 0.370 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 14 | 2009 | 40 | 0.370 |
Why?
|
| Mediodorsal Thalamic Nucleus | 2 | 2001 | 3 | 0.360 |
Why?
|
| Rodentia | 2 | 2007 | 27 | 0.360 |
Why?
|
| Hospitals, University | 1 | 2010 | 169 | 0.360 |
Why?
|
| Norepinephrine | 5 | 2008 | 276 | 0.360 |
Why?
|
| Hallucinogens | 2 | 2022 | 14 | 0.360 |
Why?
|
| GABA Antagonists | 5 | 2010 | 22 | 0.360 |
Why?
|
| Secretogranin II | 1 | 2010 | 2 | 0.350 |
Why?
|
| In Vitro Techniques | 5 | 2014 | 765 | 0.350 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 53 | 0.350 |
Why?
|
| Serotonin | 8 | 2007 | 144 | 0.350 |
Why?
|
| Receptors, GABA-B | 5 | 2003 | 10 | 0.340 |
Why?
|
| Enzyme Activation | 4 | 2020 | 791 | 0.340 |
Why?
|
| Oligonucleotides, Antisense | 4 | 2004 | 48 | 0.340 |
Why?
|
| Double-Blind Method | 7 | 2020 | 1738 | 0.340 |
Why?
|
| Protein Multimerization | 1 | 2010 | 71 | 0.340 |
Why?
|
| Schools, Medical | 1 | 2010 | 157 | 0.340 |
Why?
|
| Virulence Factors, Bordetella | 5 | 1992 | 60 | 0.340 |
Why?
|
| Up-Regulation | 4 | 2021 | 682 | 0.340 |
Why?
|
| Pertussis Toxin | 5 | 1992 | 72 | 0.340 |
Why?
|
| Maze Learning | 3 | 2005 | 138 | 0.330 |
Why?
|
| Benzodiazepines | 1 | 2010 | 130 | 0.330 |
Why?
|
| Picrotoxin | 5 | 1992 | 14 | 0.330 |
Why?
|
| Central Nervous System Sensitization | 3 | 2013 | 8 | 0.320 |
Why?
|
| Excitatory Amino Acids | 3 | 2004 | 8 | 0.320 |
Why?
|
| Integrin beta1 | 1 | 2008 | 48 | 0.320 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 214 | 0.320 |
Why?
|
| Tyrosine 3-Monooxygenase | 6 | 1994 | 71 | 0.320 |
Why?
|
| Stress, Physiological | 5 | 1995 | 215 | 0.320 |
Why?
|
| Obesity | 1 | 2015 | 1076 | 0.310 |
Why?
|
| Brain Mapping | 14 | 2009 | 532 | 0.310 |
Why?
|
| Ubiquitin | 2 | 2011 | 74 | 0.300 |
Why?
|
| Dizocilpine Maleate | 3 | 1999 | 43 | 0.300 |
Why?
|
| Biotinylation | 3 | 2012 | 27 | 0.300 |
Why?
|
| Electric Stimulation | 4 | 2013 | 218 | 0.300 |
Why?
|
| Schizophrenia | 5 | 2022 | 206 | 0.300 |
Why?
|
| Neuroglia | 5 | 2017 | 136 | 0.300 |
Why?
|
| Videotape Recording | 1 | 2007 | 43 | 0.290 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2012 | 64 | 0.290 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 69 | 0.290 |
Why?
|
| Mice, 129 Strain | 2 | 2017 | 44 | 0.290 |
Why?
|
| Dialysis | 12 | 1993 | 30 | 0.290 |
Why?
|
| Receptors, Neurotransmitter | 4 | 1992 | 31 | 0.290 |
Why?
|
| Molecular Sequence Data | 8 | 2011 | 1447 | 0.280 |
Why?
|
| Organ Culture Techniques | 3 | 2017 | 122 | 0.280 |
Why?
|
| Temperance | 1 | 2006 | 41 | 0.280 |
Why?
|
| Glutathione | 4 | 2020 | 343 | 0.280 |
Why?
|
| Drug Therapy | 1 | 2007 | 71 | 0.280 |
Why?
|
| Haloperidol | 10 | 1994 | 95 | 0.280 |
Why?
|
| Acetylcholine | 1 | 2006 | 64 | 0.280 |
Why?
|
| Psychomotor Performance | 3 | 2008 | 213 | 0.280 |
Why?
|
| Comorbidity | 3 | 2016 | 1426 | 0.280 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 1998 | 19 | 0.280 |
Why?
|
| Memory | 5 | 2005 | 214 | 0.270 |
Why?
|
| Glutamate Decarboxylase | 6 | 1995 | 18 | 0.270 |
Why?
|
| Learning | 4 | 2007 | 186 | 0.270 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 333 | 0.270 |
Why?
|
| Thyrotropin-Releasing Hormone | 7 | 1987 | 25 | 0.270 |
Why?
|
| Raphe Nuclei | 2 | 2004 | 10 | 0.270 |
Why?
|
| Nerve Degeneration | 1 | 2006 | 134 | 0.270 |
Why?
|
| Efferent Pathways | 3 | 2004 | 15 | 0.270 |
Why?
|
| Rats, Wistar | 6 | 2022 | 371 | 0.270 |
Why?
|
| Glycine | 4 | 2012 | 89 | 0.260 |
Why?
|
| Electrophysiology | 5 | 2011 | 160 | 0.260 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 951 | 0.260 |
Why?
|
| Substantia Nigra | 5 | 1995 | 102 | 0.260 |
Why?
|
| Adaptation, Psychological | 2 | 1999 | 447 | 0.260 |
Why?
|
| Naloxone | 8 | 2020 | 56 | 0.260 |
Why?
|
| Quinoxalines | 2 | 2014 | 78 | 0.260 |
Why?
|
| Amino Acid Sequence | 7 | 2011 | 1083 | 0.260 |
Why?
|
| In Situ Hybridization | 9 | 2002 | 201 | 0.260 |
Why?
|
| Alcohol Drinking | 3 | 2022 | 805 | 0.260 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2006 | 110 | 0.250 |
Why?
|
| Green Fluorescent Proteins | 4 | 2013 | 200 | 0.250 |
Why?
|
| Pyridines | 4 | 2012 | 261 | 0.250 |
Why?
|
| Orexins | 2 | 2020 | 52 | 0.250 |
Why?
|
| Pentobarbital | 6 | 1982 | 19 | 0.250 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2004 | 11 | 0.240 |
Why?
|
| Equilibrative Nucleoside Transport Proteins | 1 | 2004 | 1 | 0.240 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2016 | 151 | 0.240 |
Why?
|
| Benzazepines | 5 | 2014 | 104 | 0.240 |
Why?
|
| Social Isolation | 1 | 2004 | 40 | 0.240 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2004 | 34 | 0.240 |
Why?
|
| Drug Interactions | 5 | 2007 | 289 | 0.230 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2017 | 34 | 0.230 |
Why?
|
| Methylphenidate | 1 | 2005 | 97 | 0.230 |
Why?
|
| Down-Regulation | 4 | 2014 | 447 | 0.230 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2003 | 8 | 0.230 |
Why?
|
| Membrane Glycoproteins | 2 | 1998 | 370 | 0.230 |
Why?
|
| Behavior | 3 | 2000 | 59 | 0.230 |
Why?
|
| Dopamine Agents | 5 | 2019 | 56 | 0.230 |
Why?
|
| Rats, Transgenic | 2 | 2020 | 24 | 0.230 |
Why?
|
| Restraint, Physical | 3 | 2020 | 59 | 0.230 |
Why?
|
| Cannabinoid Receptor Agonists | 2 | 2022 | 20 | 0.220 |
Why?
|
| Homovanillic Acid | 10 | 1993 | 52 | 0.220 |
Why?
|
| Protein Precursors | 7 | 2015 | 105 | 0.220 |
Why?
|
| Calcium | 4 | 2003 | 929 | 0.220 |
Why?
|
| Adenoviridae | 1 | 2003 | 295 | 0.220 |
Why?
|
| Indoles | 3 | 2019 | 146 | 0.210 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 173 | 0.210 |
Why?
|
| Bicuculline | 4 | 2010 | 17 | 0.210 |
Why?
|
| Somatostatin | 3 | 2017 | 36 | 0.210 |
Why?
|
| Oxidation-Reduction | 6 | 2019 | 567 | 0.210 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2010 | 189 | 0.210 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 4 | 1996 | 15 | 0.210 |
Why?
|
| Prodrugs | 1 | 2022 | 54 | 0.200 |
Why?
|
| Space Perception | 2 | 1999 | 44 | 0.200 |
Why?
|
| Aspartic Acid | 3 | 2014 | 65 | 0.200 |
Why?
|
| Piperazines | 6 | 2005 | 206 | 0.200 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2022 | 88 | 0.200 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2011 | 93 | 0.200 |
Why?
|
| Ergolines | 5 | 1995 | 19 | 0.190 |
Why?
|
| Transcription Factors | 2 | 2008 | 753 | 0.190 |
Why?
|
| Smoking Cessation | 3 | 2022 | 1034 | 0.190 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 4 | 2013 | 12 | 0.190 |
Why?
|
| Fluorescent Dyes | 7 | 2005 | 191 | 0.190 |
Why?
|
| Neurons, Afferent | 2 | 1999 | 32 | 0.190 |
Why?
|
| Protein Transport | 3 | 2013 | 280 | 0.190 |
Why?
|
| Dopamine Agonists | 6 | 1997 | 68 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 101 | 0.190 |
Why?
|
| Substantia Innominata | 2 | 1991 | 3 | 0.190 |
Why?
|
| Axons | 2 | 1993 | 139 | 0.190 |
Why?
|
| Methadone | 1 | 2020 | 32 | 0.180 |
Why?
|
| Hyperphagia | 1 | 2020 | 7 | 0.180 |
Why?
|
| Receptors, Kainic Acid | 2 | 1999 | 24 | 0.180 |
Why?
|
| Autoradiography | 8 | 1999 | 94 | 0.180 |
Why?
|
| Endocannabinoids | 1 | 2020 | 32 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 2223 | 0.180 |
Why?
|
| Potassium | 4 | 2014 | 168 | 0.180 |
Why?
|
| Cells, Cultured | 5 | 2011 | 2673 | 0.180 |
Why?
|
| Cannabis | 1 | 2022 | 115 | 0.180 |
Why?
|
| Afferent Pathways | 3 | 2015 | 31 | 0.180 |
Why?
|
| Extrapyramidal Tracts | 1 | 1999 | 1 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2022 | 295 | 0.170 |
Why?
|
| Buprenorphine | 1 | 2020 | 67 | 0.170 |
Why?
|
| Receptors, Opioid, delta | 3 | 1995 | 37 | 0.170 |
Why?
|
| Allosteric Regulation | 1 | 2019 | 58 | 0.170 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2020 | 27 | 0.170 |
Why?
|
| Oxidopamine | 8 | 1998 | 42 | 0.170 |
Why?
|
| Polymers | 1 | 2021 | 244 | 0.170 |
Why?
|
| Calcium Channels, N-Type | 2 | 2019 | 7 | 0.170 |
Why?
|
| Synaptic Potentials | 1 | 2019 | 8 | 0.170 |
Why?
|
| Nicotine | 3 | 2022 | 350 | 0.170 |
Why?
|
| Fluphenazine | 5 | 2003 | 19 | 0.170 |
Why?
|
| Alternative Splicing | 1 | 1999 | 93 | 0.170 |
Why?
|
| Antipsychotic Agents | 2 | 2021 | 247 | 0.170 |
Why?
|
| Gene Expression | 5 | 2013 | 770 | 0.170 |
Why?
|
| Matrix Metalloproteinases | 1 | 2020 | 223 | 0.160 |
Why?
|
| Phosphorylation | 4 | 2019 | 1200 | 0.160 |
Why?
|
| Quinolinic Acids | 4 | 1992 | 6 | 0.160 |
Why?
|
| Propanolamines | 2 | 2010 | 70 | 0.160 |
Why?
|
| Receptors, Neurotensin | 5 | 2008 | 17 | 0.160 |
Why?
|
| Ibotenic Acid | 2 | 1998 | 9 | 0.160 |
Why?
|
| Nerve Endings | 3 | 1993 | 14 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2019 | 108 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 196 | 0.160 |
Why?
|
| Adult | 10 | 2020 | 21403 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 146 | 0.160 |
Why?
|
| Second Messenger Systems | 1 | 1998 | 53 | 0.160 |
Why?
|
| Genetic Variation | 1 | 1999 | 220 | 0.160 |
Why?
|
| Calcium Channels, L-Type | 2 | 2014 | 34 | 0.160 |
Why?
|
| Xanthenes | 4 | 2012 | 18 | 0.160 |
Why?
|
| Pons | 2 | 1999 | 35 | 0.160 |
Why?
|
| Azepines | 1 | 2018 | 15 | 0.160 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 95 | 0.160 |
Why?
|
| Sweetening Agents | 1 | 2018 | 23 | 0.160 |
Why?
|
| Receptor, trkB | 1 | 2018 | 27 | 0.160 |
Why?
|
| Random Allocation | 5 | 2020 | 442 | 0.160 |
Why?
|
| KCNQ Potassium Channels | 1 | 2018 | 8 | 0.160 |
Why?
|
| Reinforcement Schedule | 1 | 2018 | 59 | 0.160 |
Why?
|
| Middle Aged | 9 | 2020 | 21147 | 0.160 |
Why?
|
| Catecholamines | 3 | 1989 | 73 | 0.150 |
Why?
|
| Genes, Reporter | 1 | 2018 | 191 | 0.150 |
Why?
|
| Pilot Projects | 5 | 2020 | 1342 | 0.150 |
Why?
|
| Enzyme Inhibitors | 4 | 2008 | 659 | 0.150 |
Why?
|
| Drug Tolerance | 4 | 2003 | 80 | 0.150 |
Why?
|
| Quinpirole | 6 | 1997 | 26 | 0.150 |
Why?
|
| Perception | 1 | 1999 | 189 | 0.150 |
Why?
|
| Drug Synergism | 3 | 2005 | 260 | 0.150 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 58 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2020 | 7029 | 0.140 |
Why?
|
| Benzamides | 1 | 2018 | 156 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 378 | 0.140 |
Why?
|
| Body Temperature Regulation | 5 | 1985 | 29 | 0.140 |
Why?
|
| Injections, Intraperitoneal | 3 | 2001 | 89 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 955 | 0.140 |
Why?
|
| Animals, Newborn | 4 | 2020 | 396 | 0.140 |
Why?
|
| Immunoblotting | 3 | 2005 | 254 | 0.140 |
Why?
|
| Vesicular Glutamate Transport Proteins | 1 | 2016 | 2 | 0.140 |
Why?
|
| Receptors, Ionotropic Glutamate | 1 | 2016 | 2 | 0.140 |
Why?
|
| Dependovirus | 2 | 2013 | 34 | 0.140 |
Why?
|
| Histone Deacetylases | 1 | 2017 | 99 | 0.140 |
Why?
|
| Protein Binding | 3 | 2019 | 1027 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 615 | 0.130 |
Why?
|
| Tachykinins | 4 | 1998 | 8 | 0.130 |
Why?
|
| Amino Acid Transport System X-AG | 3 | 2008 | 11 | 0.130 |
Why?
|
| Sex Factors | 1 | 2020 | 1266 | 0.130 |
Why?
|
| Septum Pellucidum | 4 | 1985 | 7 | 0.130 |
Why?
|
| Resorcinols | 2 | 2008 | 8 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2008 | 1330 | 0.130 |
Why?
|
| Propranolol | 1 | 1996 | 103 | 0.130 |
Why?
|
| Adenosine Diphosphate Ribose | 2 | 1992 | 14 | 0.130 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2016 | 56 | 0.130 |
Why?
|
| Diffusion | 3 | 2012 | 90 | 0.130 |
Why?
|
| Thalamic Nuclei | 1 | 1995 | 9 | 0.130 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1995 | 150 | 0.130 |
Why?
|
| Pituitary-Adrenal System | 1 | 1995 | 138 | 0.130 |
Why?
|
| SNARE Proteins | 1 | 2015 | 5 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 170 | 0.130 |
Why?
|
| Inhalant Abuse | 1 | 2015 | 7 | 0.130 |
Why?
|
| Dietary Sucrose | 1 | 2015 | 18 | 0.130 |
Why?
|
| Age Factors | 1 | 2020 | 1864 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 848 | 0.120 |
Why?
|
| Clozapine | 1 | 2015 | 46 | 0.120 |
Why?
|
| Motor Neurons | 2 | 1998 | 98 | 0.120 |
Why?
|
| Apamin | 2 | 1994 | 13 | 0.120 |
Why?
|
| Craving | 1 | 2016 | 200 | 0.120 |
Why?
|
| Multiple Chemical Sensitivity | 1 | 1994 | 5 | 0.120 |
Why?
|
| Injections | 7 | 1991 | 119 | 0.120 |
Why?
|
| Toluene | 1 | 2015 | 37 | 0.120 |
Why?
|
| Dorsomedial Hypothalamic Nucleus | 1 | 1994 | 2 | 0.120 |
Why?
|
| Solvents | 1 | 2015 | 109 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2005 | 160 | 0.120 |
Why?
|
| Piperidines | 2 | 2011 | 123 | 0.120 |
Why?
|
| Tetrodotoxin | 4 | 2005 | 26 | 0.120 |
Why?
|
| Dopamine D2 Receptor Antagonists | 1 | 2013 | 13 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 1994 | 331 | 0.120 |
Why?
|
| Organ Specificity | 3 | 1999 | 167 | 0.110 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 2003 | 35 | 0.110 |
Why?
|
| Opsins | 1 | 2013 | 19 | 0.110 |
Why?
|
| Adolescent | 4 | 2022 | 8912 | 0.110 |
Why?
|
| Marijuana Abuse | 1 | 2017 | 251 | 0.110 |
Why?
|
| Nicotinic Agonists | 1 | 2014 | 111 | 0.110 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 81 | 0.110 |
Why?
|
| Apomorphine | 2 | 1994 | 48 | 0.110 |
Why?
|
| Fear | 2 | 2017 | 239 | 0.110 |
Why?
|
| Acute Disease | 2 | 2019 | 658 | 0.110 |
Why?
|
| Genetic Therapy | 1 | 2015 | 291 | 0.110 |
Why?
|
| Wakefulness-Promoting Agents | 1 | 2012 | 6 | 0.110 |
Why?
|
| Biophysics | 1 | 2012 | 41 | 0.110 |
Why?
|
| Amino Acid Transport Systems | 1 | 2012 | 3 | 0.110 |
Why?
|
| GABA-B Receptor Agonists | 2 | 2003 | 5 | 0.110 |
Why?
|
| Age of Onset | 1 | 2013 | 188 | 0.110 |
Why?
|
| GABA-B Receptor Antagonists | 2 | 2003 | 3 | 0.100 |
Why?
|
| Hippocampus | 3 | 2008 | 471 | 0.100 |
Why?
|
| Tritium | 2 | 2010 | 101 | 0.100 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 62 | 0.100 |
Why?
|
| Actin Cytoskeleton | 1 | 2012 | 37 | 0.100 |
Why?
|
| Phenylacetates | 1 | 2012 | 18 | 0.100 |
Why?
|
| Endorphins | 1 | 1992 | 32 | 0.100 |
Why?
|
| Transfection | 3 | 2012 | 782 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2006 | 786 | 0.100 |
Why?
|
| Chromones | 2 | 2003 | 33 | 0.100 |
Why?
|
| Amino Acids, Neutral | 1 | 1991 | 1 | 0.100 |
Why?
|
| Injections, Intraventricular | 6 | 1996 | 50 | 0.100 |
Why?
|
| Carbachol | 2 | 1989 | 34 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 1996 | 1753 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2015 | 190 | 0.100 |
Why?
|
| Hydroxyindoleacetic Acid | 5 | 1993 | 36 | 0.100 |
Why?
|
| Thiazoles | 1 | 2012 | 95 | 0.100 |
Why?
|
| Embryo, Mammalian | 2 | 2012 | 176 | 0.100 |
Why?
|
| Stereotyped Behavior | 3 | 2005 | 42 | 0.100 |
Why?
|
| Quinolinic Acid | 4 | 1992 | 11 | 0.100 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2011 | 73 | 0.100 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2011 | 53 | 0.100 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 39 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2011 | 85 | 0.100 |
Why?
|
| Tissue Distribution | 5 | 1997 | 282 | 0.090 |
Why?
|
| Protein Isoforms | 3 | 2006 | 246 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2011 | 152 | 0.090 |
Why?
|
| Bee Venoms | 1 | 1990 | 2 | 0.090 |
Why?
|
| Amphetamines | 3 | 1998 | 10 | 0.090 |
Why?
|
| Medicine | 1 | 2010 | 52 | 0.090 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2010 | 15 | 0.090 |
Why?
|
| Brain Diseases | 1 | 2011 | 78 | 0.090 |
Why?
|
| Phenoxyacetates | 1 | 2010 | 1 | 0.090 |
Why?
|
| Glucose | 1 | 1992 | 307 | 0.090 |
Why?
|
| Atropine | 2 | 1988 | 29 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 142 | 0.090 |
Why?
|
| Clenbuterol | 1 | 2010 | 9 | 0.090 |
Why?
|
| Efficiency, Organizational | 1 | 2010 | 61 | 0.090 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2010 | 7 | 0.090 |
Why?
|
| Raclopride | 2 | 2005 | 15 | 0.090 |
Why?
|
| Food Deprivation | 1 | 2010 | 22 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 307 | 0.090 |
Why?
|
| Biogenic Amines | 4 | 1991 | 15 | 0.090 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2010 | 92 | 0.090 |
Why?
|
| Seizures | 1 | 1992 | 279 | 0.090 |
Why?
|
| Fetal Diseases | 1 | 1990 | 64 | 0.090 |
Why?
|
| Databases, Protein | 1 | 2010 | 49 | 0.090 |
Why?
|
| Calcium Channel Blockers | 2 | 2001 | 138 | 0.090 |
Why?
|
| Procaine | 2 | 1999 | 9 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 51 | 0.080 |
Why?
|
| Infusion Pumps, Implantable | 2 | 2003 | 26 | 0.080 |
Why?
|
| Sodium Chloride | 3 | 1995 | 136 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 1038 | 0.080 |
Why?
|
| Feedback | 2 | 2003 | 90 | 0.080 |
Why?
|
| Genes, Immediate-Early | 1 | 2009 | 13 | 0.080 |
Why?
|
| Synaptic Membranes | 1 | 2008 | 8 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2012 | 706 | 0.080 |
Why?
|
| Microscopy, Electron | 2 | 2008 | 351 | 0.080 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2008 | 15 | 0.080 |
Why?
|
| Evoked Potentials | 1 | 2009 | 61 | 0.080 |
Why?
|
| Crosses, Genetic | 1 | 2008 | 60 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2009 | 84 | 0.080 |
Why?
|
| Habits | 1 | 2008 | 14 | 0.080 |
Why?
|
| Helplessness, Learned | 1 | 2008 | 9 | 0.080 |
Why?
|
| Young Adult | 1 | 2020 | 5717 | 0.080 |
Why?
|
| Myristates | 1 | 2008 | 21 | 0.080 |
Why?
|
| Hydroxydopamines | 5 | 1990 | 25 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1990 | 154 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 181 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 700 | 0.080 |
Why?
|
| Carbon Monoxide | 1 | 2008 | 58 | 0.080 |
Why?
|
| Binding Sites | 3 | 2000 | 631 | 0.080 |
Why?
|
| Mecamylamine | 1 | 1988 | 9 | 0.080 |
Why?
|
| Computational Biology | 1 | 2010 | 190 | 0.080 |
Why?
|
| Protein Kinase C | 3 | 2005 | 270 | 0.080 |
Why?
|
| Varenicline | 2 | 2022 | 98 | 0.080 |
Why?
|
| Binding, Competitive | 2 | 2003 | 165 | 0.080 |
Why?
|
| Stereotaxic Techniques | 3 | 2005 | 35 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 710 | 0.080 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 1987 | 79 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 174 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 47 | 0.080 |
Why?
|
| Quinolines | 1 | 2008 | 48 | 0.080 |
Why?
|
| Cullin Proteins | 1 | 2007 | 14 | 0.070 |
Why?
|
| Leupeptins | 1 | 2007 | 23 | 0.070 |
Why?
|
| Acid Ceramidase | 1 | 2008 | 85 | 0.070 |
Why?
|
| Antioxidants | 1 | 2010 | 304 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2011 | 310 | 0.070 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2007 | 73 | 0.070 |
Why?
|
| Sexual Behavior, Animal | 1 | 1987 | 13 | 0.070 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2006 | 4 | 0.070 |
Why?
|
| Cholinergic Fibers | 1 | 2006 | 27 | 0.070 |
Why?
|
| Research | 1 | 2008 | 214 | 0.070 |
Why?
|
| Drinking | 1 | 2006 | 35 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2005 | 532 | 0.070 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 58 | 0.070 |
Why?
|
| Analgesics | 3 | 1995 | 118 | 0.070 |
Why?
|
| Muscarinic Antagonists | 1 | 2006 | 54 | 0.070 |
Why?
|
| Aged | 2 | 2020 | 14862 | 0.070 |
Why?
|
| Adrenalectomy | 2 | 1996 | 17 | 0.070 |
Why?
|
| Kinetics | 4 | 1992 | 1047 | 0.070 |
Why?
|
| Pseudopodia | 1 | 2006 | 16 | 0.070 |
Why?
|
| Smoking | 1 | 2014 | 1452 | 0.070 |
Why?
|
| Dihydro-beta-Erythroidine | 1 | 2005 | 5 | 0.070 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 3 | 1992 | 7 | 0.070 |
Why?
|
| Crack Cocaine | 1 | 2006 | 20 | 0.070 |
Why?
|
| Spinal Cord | 3 | 2012 | 244 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2010 | 617 | 0.070 |
Why?
|
| Receptors, Presynaptic | 1 | 2005 | 6 | 0.060 |
Why?
|
| Receptors, Nicotinic | 1 | 2005 | 41 | 0.060 |
Why?
|
| Consummatory Behavior | 1 | 2005 | 8 | 0.060 |
Why?
|
| Avoidance Learning | 2 | 2005 | 58 | 0.060 |
Why?
|
| Reflex | 1 | 2005 | 21 | 0.060 |
Why?
|
| Carnitine Acyltransferases | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 230 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2007 | 215 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2006 | 102 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 689 | 0.060 |
Why?
|
| Genetic Code | 2 | 1995 | 4 | 0.060 |
Why?
|
| Carbon Isotopes | 1 | 2005 | 54 | 0.060 |
Why?
|
| Peptides | 2 | 2005 | 455 | 0.060 |
Why?
|
| Iontophoresis | 2 | 1995 | 7 | 0.060 |
Why?
|
| Food | 1 | 2005 | 52 | 0.060 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2004 | 9 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 81 | 0.060 |
Why?
|
| Nucleoside Transport Proteins | 1 | 2004 | 4 | 0.060 |
Why?
|
| Blotting, Northern | 2 | 1994 | 189 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2005 | 113 | 0.060 |
Why?
|
| Cholecystokinin | 3 | 1994 | 29 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2005 | 219 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 1985 | 93 | 0.060 |
Why?
|
| Sulfur Isotopes | 1 | 2003 | 2 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 742 | 0.060 |
Why?
|
| South Carolina | 1 | 2010 | 2752 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2005 | 240 | 0.060 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2003 | 17 | 0.060 |
Why?
|
| Enzyme Activators | 1 | 2003 | 14 | 0.060 |
Why?
|
| Radioligand Assay | 1 | 2003 | 109 | 0.060 |
Why?
|
| Algorithms | 1 | 2010 | 1196 | 0.060 |
Why?
|
| Precipitin Tests | 1 | 2003 | 88 | 0.060 |
Why?
|
| Synaptic Vesicles | 1 | 2003 | 18 | 0.060 |
Why?
|
| Phosphotransferases | 1 | 2003 | 16 | 0.060 |
Why?
|
| Models, Animal | 2 | 2019 | 252 | 0.060 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 57 | 0.060 |
Why?
|
| Dipeptides | 2 | 1995 | 89 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 507 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 317 | 0.060 |
Why?
|
| Maleimides | 2 | 2005 | 15 | 0.060 |
Why?
|
| Expectorants | 1 | 2003 | 5 | 0.060 |
Why?
|
| Osmolar Concentration | 3 | 1993 | 134 | 0.060 |
Why?
|
| Neural Conduction | 2 | 2005 | 24 | 0.060 |
Why?
|
| Conditioning, Classical | 2 | 2019 | 57 | 0.060 |
Why?
|
| Perfusion | 1 | 2003 | 131 | 0.060 |
Why?
|
| Stimulation, Chemical | 3 | 2000 | 57 | 0.050 |
Why?
|
| Aminobutyrates | 1 | 2003 | 94 | 0.050 |
Why?
|
| Diencephalon | 2 | 1999 | 4 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2003 | 99 | 0.050 |
Why?
|
| Action Potentials | 2 | 2018 | 223 | 0.050 |
Why?
|
| Cognition | 1 | 2006 | 513 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2003 | 304 | 0.050 |
Why?
|
| Histamine | 1 | 1982 | 52 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 627 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1174 | 0.050 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2001 | 13 | 0.050 |
Why?
|
| Analgesia | 1 | 1982 | 58 | 0.050 |
Why?
|
| Ion Channels | 1 | 2002 | 72 | 0.050 |
Why?
|
| Premedication | 1 | 2001 | 49 | 0.050 |
Why?
|
| Depression | 1 | 2008 | 943 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2002 | 223 | 0.050 |
Why?
|
| Sympathectomy, Chemical | 2 | 1992 | 6 | 0.050 |
Why?
|
| Iodine Radioisotopes | 2 | 1992 | 119 | 0.050 |
Why?
|
| 5-Hydroxytryptophan | 2 | 1991 | 4 | 0.050 |
Why?
|
| Dynorphins | 2 | 1994 | 69 | 0.050 |
Why?
|
| Decision Making | 1 | 2004 | 410 | 0.050 |
Why?
|
| Histocytochemistry | 2 | 1994 | 149 | 0.040 |
Why?
|
| Cerebrospinal Fluid | 1 | 1980 | 23 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2000 | 10 | 0.040 |
Why?
|
| Pregnancy, Animal | 1 | 2020 | 27 | 0.040 |
Why?
|
| Electrochemistry | 2 | 1998 | 70 | 0.040 |
Why?
|
| Osmosis | 1 | 2020 | 38 | 0.040 |
Why?
|
| Caudate Nucleus | 3 | 2002 | 56 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 2000 | 83 | 0.040 |
Why?
|
| Pregnancy | 2 | 2020 | 2334 | 0.040 |
Why?
|
| Odorants | 1 | 2020 | 52 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 322 | 0.040 |
Why?
|
| Telencephalon | 1 | 1999 | 6 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 1999 | 136 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2020 | 75 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2020 | 107 | 0.040 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 1999 | 9 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 426 | 0.040 |
Why?
|
| Putamen | 2 | 2002 | 35 | 0.040 |
Why?
|
| Biological Transport | 2 | 2005 | 210 | 0.040 |
Why?
|
| Sympatholytics | 1 | 1998 | 11 | 0.040 |
Why?
|
| Video Recording | 1 | 2000 | 145 | 0.040 |
Why?
|
| Caffeine | 2 | 1991 | 81 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 1998 | 26 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 346 | 0.040 |
Why?
|
| Phenylenediamines | 1 | 2018 | 16 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 107 | 0.040 |
Why?
|
| Membrane Transport Modulators | 1 | 2018 | 23 | 0.040 |
Why?
|
| Olfactory Bulb | 2 | 1991 | 14 | 0.040 |
Why?
|
| Carbamates | 1 | 2018 | 41 | 0.040 |
Why?
|
| Sulpiride | 1 | 1997 | 20 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 56 | 0.040 |
Why?
|
| Models, Molecular | 1 | 1999 | 546 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 284 | 0.040 |
Why?
|
| Neurokinin A | 3 | 1985 | 5 | 0.040 |
Why?
|
| Potassium Chloride | 3 | 2005 | 45 | 0.030 |
Why?
|
| Mental Recall | 1 | 2016 | 72 | 0.030 |
Why?
|
| Corticosterone | 1 | 1996 | 51 | 0.030 |
Why?
|
| Atenolol | 1 | 1996 | 20 | 0.030 |
Why?
|
| Dihydroxyphenylalanine | 2 | 1988 | 13 | 0.030 |
Why?
|
| Synapsins | 1 | 2015 | 11 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 499 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2007 | 260 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2015 | 63 | 0.030 |
Why?
|
| Phytohemagglutinins | 2 | 1992 | 16 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1991 | 618 | 0.030 |
Why?
|
| Habituation, Psychophysiologic | 1 | 1995 | 22 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 79 | 0.030 |
Why?
|
| Individuality | 1 | 1994 | 44 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1994 | 11 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1994 | 37 | 0.030 |
Why?
|
| Thiazolidines | 2 | 2012 | 23 | 0.030 |
Why?
|
| Hydroxylation | 1 | 1993 | 41 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 137 | 0.030 |
Why?
|
| Protein Kinases | 1 | 1994 | 122 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 411 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2013 | 96 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1994 | 186 | 0.030 |
Why?
|
| Exocytosis | 1 | 2013 | 34 | 0.030 |
Why?
|
| Axonal Transport | 1 | 1992 | 9 | 0.030 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2012 | 30 | 0.030 |
Why?
|
| Cortactin | 1 | 2012 | 3 | 0.030 |
Why?
|
| Halorhodopsins | 1 | 2012 | 1 | 0.030 |
Why?
|
| Ligands | 1 | 2013 | 317 | 0.030 |
Why?
|
| Polymerization | 1 | 2012 | 17 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 397 | 0.030 |
Why?
|
| Post-Synaptic Density | 1 | 2012 | 7 | 0.030 |
Why?
|
| Archaeal Proteins | 1 | 2012 | 5 | 0.030 |
Why?
|
| Proton Pumps | 1 | 2012 | 13 | 0.030 |
Why?
|
| Tyrosine | 1 | 1993 | 196 | 0.030 |
Why?
|
| Veratridine | 1 | 1992 | 4 | 0.030 |
Why?
|
| Magnesium Chloride | 1 | 1992 | 8 | 0.030 |
Why?
|
| Sodium Channels | 1 | 1992 | 24 | 0.030 |
Why?
|
| Verapamil | 1 | 1992 | 30 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 35 | 0.030 |
Why?
|
| Autoreceptors | 1 | 2012 | 1 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 132 | 0.030 |
Why?
|
| Red Nucleus | 1 | 1992 | 3 | 0.030 |
Why?
|
| Pentylenetetrazole | 1 | 1992 | 10 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2012 | 85 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2012 | 155 | 0.030 |
Why?
|
| Salicylamides | 1 | 1991 | 18 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 1515 | 0.030 |
Why?
|
| Catalysis | 1 | 1992 | 123 | 0.030 |
Why?
|
| Acetonitriles | 1 | 1991 | 6 | 0.020 |
Why?
|
| Microchemistry | 1 | 1991 | 19 | 0.020 |
Why?
|
| Nipecotic Acids | 1 | 1991 | 11 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2012 | 229 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1991 | 66 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2011 | 15 | 0.020 |
Why?
|
| Sindbis Virus | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 329 | 0.020 |
Why?
|
| Phylogeny | 1 | 2012 | 197 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1991 | 35 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 57 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 95 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 46 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 43 | 0.020 |
Why?
|
| Buffers | 1 | 1991 | 31 | 0.020 |
Why?
|
| Acclimatization | 1 | 1991 | 14 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2011 | 27 | 0.020 |
Why?
|
| Phenols | 1 | 2011 | 73 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 782 | 0.020 |
Why?
|
| Hypothalamus | 1 | 1991 | 78 | 0.020 |
Why?
|
| Receptors, Angiotensin | 1 | 1990 | 59 | 0.020 |
Why?
|
| Litter Size | 1 | 1990 | 14 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 218 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 312 | 0.020 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 1991 | 133 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 247 | 0.020 |
Why?
|
| Quinuclidinyl Benzilate | 1 | 1990 | 10 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1990 | 17 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1992 | 737 | 0.020 |
Why?
|
| Locus Coeruleus | 1 | 1990 | 55 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 1990 | 120 | 0.020 |
Why?
|
| Reference Values | 1 | 1991 | 579 | 0.020 |
Why?
|
| H-Reflex | 1 | 1989 | 15 | 0.020 |
Why?
|
| MPTP Poisoning | 1 | 1989 | 10 | 0.020 |
Why?
|
| Angiotensin II | 1 | 1990 | 220 | 0.020 |
Why?
|
| Sincalide | 2 | 1986 | 12 | 0.020 |
Why?
|
| Birth Weight | 1 | 1990 | 186 | 0.020 |
Why?
|
| Sleep | 2 | 1982 | 263 | 0.020 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2008 | 45 | 0.020 |
Why?
|
| Desipramine | 1 | 2008 | 47 | 0.020 |
Why?
|
| Pain | 2 | 1982 | 472 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2011 | 342 | 0.020 |
Why?
|
| Bombesin | 2 | 1984 | 4 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 506 | 0.020 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1987 | 20 | 0.020 |
Why?
|
| Rats, Inbred Lew | 2 | 2002 | 150 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 251 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 175 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 195 | 0.020 |
Why?
|
| Tiopronin | 1 | 1986 | 1 | 0.020 |
Why?
|
| Thiorphan | 1 | 1986 | 1 | 0.020 |
Why?
|
| Movement | 1 | 1988 | 179 | 0.020 |
Why?
|
| Capsaicin | 1 | 1986 | 5 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2006 | 134 | 0.020 |
Why?
|
| Biomarkers | 1 | 1992 | 1593 | 0.020 |
Why?
|
| RNA | 1 | 2007 | 171 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2006 | 200 | 0.020 |
Why?
|
| Visual Perception | 1 | 2007 | 124 | 0.020 |
Why?
|
| Aconitine | 1 | 2005 | 5 | 0.020 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2005 | 9 | 0.020 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 1 | 1985 | 1 | 0.020 |
Why?
|
| Nicotinic Antagonists | 1 | 2005 | 11 | 0.020 |
Why?
|
| Enkephalin, Leucine | 1 | 1985 | 4 | 0.020 |
Why?
|
| Affect | 1 | 2007 | 218 | 0.020 |
Why?
|
| Nociceptors | 2 | 1984 | 9 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2006 | 107 | 0.020 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2006 | 71 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2005 | 60 | 0.020 |
Why?
|
| Haplorhini | 1 | 1985 | 44 | 0.020 |
Why?
|
| Aging | 1 | 2011 | 911 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 282 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 301 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2005 | 77 | 0.020 |
Why?
|
| Species Specificity | 2 | 1982 | 303 | 0.020 |
Why?
|
| Ceramides | 1 | 2008 | 578 | 0.020 |
Why?
|
| Cats | 1 | 1985 | 292 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2005 | 109 | 0.010 |
Why?
|
| Nerve Fibers | 1 | 1984 | 77 | 0.010 |
Why?
|
| Hypothalamic Hormones | 1 | 1984 | 13 | 0.010 |
Why?
|
| Pituitary Hormones | 1 | 1984 | 16 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1984 | 248 | 0.010 |
Why?
|
| Swine | 1 | 1985 | 672 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 1752 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 525 | 0.010 |
Why?
|
| Kainic Acid | 1 | 1981 | 44 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 1641 | 0.010 |
Why?
|
| Hospitalization | 1 | 2007 | 978 | 0.010 |
Why?
|
| Body Temperature | 1 | 1982 | 116 | 0.010 |
Why?
|
| Reaction Time | 1 | 1982 | 170 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 1981 | 86 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1981 | 19 | 0.010 |
Why?
|
| Receptors, Cholinergic | 1 | 1981 | 30 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 1034 | 0.010 |
Why?
|
| Brain Stem | 1 | 1981 | 46 | 0.010 |
Why?
|
| Receptors, Muscarinic | 1 | 1981 | 44 | 0.010 |
Why?
|
| Hypothermia | 1 | 1980 | 37 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 3259 | 0.010 |
Why?
|
| Temperature | 1 | 1980 | 341 | 0.010 |
Why?
|
| Stroke | 1 | 2011 | 2163 | 0.010 |
Why?
|
| Receptors, Somatostatin | 1 | 1997 | 7 | 0.010 |
Why?
|
| Electrodes | 1 | 1997 | 147 | 0.010 |
Why?
|
| Anesthesia | 1 | 1997 | 120 | 0.010 |
Why?
|
| Base Sequence | 1 | 1997 | 1015 | 0.010 |
Why?
|
| Receptors, Dopamine D3 | 1 | 1994 | 12 | 0.010 |
Why?
|
| DNA | 1 | 1997 | 597 | 0.010 |
Why?
|
| Oxazines | 1 | 1991 | 10 | 0.010 |
Why?
|
| Benzoxazines | 1 | 1991 | 20 | 0.010 |
Why?
|
| Wheat Germ Agglutinins | 1 | 1991 | 5 | 0.010 |
Why?
|
| Horseradish Peroxidase | 1 | 1991 | 27 | 0.010 |
Why?
|
| 1-Sarcosine-8-Isoleucine Angiotensin II | 1 | 1990 | 5 | 0.010 |
Why?
|
| Reflex, Monosynaptic | 1 | 1989 | 2 | 0.010 |
Why?
|
| Spectrum Analysis | 1 | 1990 | 81 | 0.010 |
Why?
|
| Vagotomy | 1 | 1986 | 9 | 0.000 |
Why?
|
| Cebus | 1 | 1985 | 9 | 0.000 |
Why?
|
| Macaca | 1 | 1985 | 24 | 0.000 |
Why?
|
| Fenclonine | 1 | 1984 | 2 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1985 | 196 | 0.000 |
Why?
|
| MSH Release-Inhibiting Hormone | 1 | 1984 | 1 | 0.000 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1984 | 32 | 0.000 |
Why?
|
| Hydrazines | 1 | 1983 | 23 | 0.000 |
Why?
|
| Muscle Relaxation | 1 | 1982 | 31 | 0.000 |
Why?
|
| Phenobarbital | 1 | 1981 | 25 | 0.000 |
Why?
|